Vasculox
Saint Louis, US · Delaware corporation · 2 known investors
Find your way into Vasculox
Sign up to see every warm intro you have to Vasculox
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Vasculox team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
KL
Kalthleen L. BeckmannExecutive
RW
Robert W. KarrExecutive
PM
Pamela ManningExecutive
WF
William FrazierNamed on SEC filing
Board
JM

John McKearnBoard directorSenior Advisor at RiverVest Venture Partners, focused on early-stage biotech
CB
Charles BoltenBoard director
BS
Bobby Sandage, Jr.Board director
DB
Dan BroderickBoard director
Investors · 2
RiverVest Venture PartnersreportedSt. Louis · $500K – $3M
How we know: board seat on SEC Form D · funding news · Not right? Tell us
Roche Venture FundreportedBasel · $648K – $3.2M
How we know: funding news · Not right? Tell us
Funding
SEC filings, press & company announcements$34.4M disclosed across 2 of 3 rounds · 2014–2016
- Undisclosed amountSeries AAug 2016Source ↗
▶$33.2MraisedAug 2016 · 12 investors · PharmaceuticalsRule 506(b)
▶$33.2MraisedAug 2016 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John McKearnDirector
- John DonovanExecutive Officer, Director
- James StutzExecutive Officer
- Carole L. NuechterleinDirector
- Pamela T. ManningExecutive Officer
- Robert W. KarrExecutive Officer
- Jill CarrollDirector
- Peter MoldtDirector
- Offering amount
- $86.3M
- Amount sold
- $33.2M
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedFeb 2015 · 3 investors · PharmaceuticalsRule 506(b)
▶$1.3MraisedFeb 2015 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kalthleen L. BeckmannExecutive Officer
- Charles BoltenDirector
- Bobby Sandage, Jr.Director
- William FrazierDirector
- Robert W. KarrExecutive Officer, Director
- Pamela ManningExecutive Officer
- John McKearnDirector
- Dan BroderickDirector
- Offering amount
- $2.8M
- Amount sold
- $1.3M
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Vasculox's investors?
- Vasculox's investors include RiverVest Venture Partners, Roche Venture Fund.
- How much funding has Vasculox raised?
- Vasculox has disclosed $34.4M raised across 2 of its 3 known rounds.
- Where is Vasculox headquartered?
- Vasculox is headquartered in Saint Louis, US.
